Dr. Cusnir on the Utility of Regorafenib in Gastric Cancer


Mike Cusnir, MD, discusses the utility of regorafenib (Stivarga) in gastric cancer.

Mike Cusnir, MD, co-director of Gastrointestinal Malignancies at Mount Sinai Medical Center, discusses the utility of regorafenib (Stivarga) in gastric cancer.

Regorafenib is still in the early stages of development in gastric cancer, says Cusnir. Although regorafenib has shown activity in this space, it is also one of the more toxic agents. As such, it is unknown what its optimal role will be in the treatment paradigm.

In colorectal cancer, the phase II ReDOS trial demonstrated that a dose-escalation strategy could be used with regorafenib to reduce associated adverse events and maintain efficacy; however, it is unknown whether the same holds true in gastric cancer. In the absence of those data, the field is looking toward larger confirmatory trials to establish whether regorafenib has a role in subsequent lines of gastric cancer treatment, concludes Cusnir.  

Related Videos
Milind Javle, MD; and Rachna Shroff, MD, MS, FASCO
Hetty E. Carraway, MD, MBA, staff associate professor, Department of Medicine, School of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University; member, Immune Oncology Program, Case Comprehensive Cancer Center; vice chair, Strategy and Enterprise Development, Taussig Cancer Institute, Division of Hematologic Oncology and Blood Disorders, Cleveland Clinic
David A. Braun, MD, PhD, assistant professor, medicine (medical oncology), Louis Goodman and Alfred Gilman Yale Scholar, member, Center of Molecular and Cellular Oncology, Yale Cancer Center
Julia Foldi, MD, PhD
Vikram M. Narayan, MD
C. Ola Landgren, MD, PhD
 Milind Javle, MD, and Rachna Shroff, MD, MS, FASCO
Milind Javle, MD; Rachna Shroff, MD, MS, FASCO; Steven Scott West